CLPTM1L: A Potential Drug Target and Biomarker for Cisplatin Resistance

Target Name: CLPTM1L

NCBI ID: G81037

CLPTM1L

CLPTM1L: A Potential Drug Target and Biomarker for Cisplatin Resistance

Introduction

Cisplatin is a chemotherapy drug that has been widely used to treat various cancers. However, its effectiveness is limited by its ability to cross the blood-brain barrier and resistance to treatment. CLPTM1L, a protein that is expressed in various tissues and cells, has been identified as a potential drug target and biomarker for cisplatin resistance.

Reconstruction of the CLPTM1L Protein

CLPTM1L is a 22-kDa protein that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. It is composed of two distinct domains: an N-terminal transmembrane domain and a C-terminal cytoplasmic domain. The N-terminal domain contains a putative G-protein-coupled receptor (GPCR) domain, which is responsible for ligand binding and signal transduction. The C-terminal domain contains a unique structural domain, known as the M1-M2 region, which is involved in the formation of a complex with other proteins, including the drug N-acetylaspartate (NAA).

Expression and Localization of CLPTM1L

CLPTM1L is expressed in various tissues and cells, including the brain, where it is predominantly expressed in the astrocytes and microglia. The expression level of CLPTM1L is also known to be affected by various factors, such as age, gender, and disease. For example , high expression of CLPTM1L has been observed in individuals with Alzheimer's disease, suggesting that it may be a potential biomarker for this disease.

Drug Sensitivity and Resistance

CLPTM1L has been shown to be involved in cisplatin resistance. Cisplatin-resistant cancer cells are less responsive to the anti-cancer effects of cisplatin, leading to a decreased treatment effect and increased patient outcomes. Several studies have shown that CLPTM1L is involved in the development and maintenance of cisplatin resistance in various cancer types, including breast, ovarian, and colorectal cancers.

Despite its potential as a drug target, CLPTM1L has not yet been fully characterized as a drug target or biomarker. Further research is needed to determine the exact role of CLPTM1L in cisplatin resistance and its potential as a drug target.

Conclusion

CLPTM1L is a protein that has been identified as a potential drug target and biomarker for cisplatin resistance. Its expression is primarily found in the brain and various tissues, and its function is involved in the development and maintenance of cisplatin resistance. Further research is needed to fully characterize CLPTM1L as a drug target or biomarker and to determine its exact role in cisplatin resistance. If CLPTM1L is indeed a potential drug target, it may have implications for the treatment of various cancers with high rates of cisplatin resistance.

Protein Name: CLPTM1 Like

Functions: Scramblase that mediates the translocation of glucosaminylphosphatidylinositol (alpha-D-GlcN-(1-6)-(1,2-diacyl-sn-glycero-3-phospho)-1D-myo-inositol, GlcN-PI) across the endoplasmic reticulum (ER) membrane, from the cytosolic leaflet to the luminal leaflet of the ER membrane, where it participates in the biosynthesis of glycosylphosphatidylinositol (GPI) (PubMed:35344438). GPI is a lipid glycoconjugate involved in post-translational modification of proteins (PubMed:35344438). Can also translocate 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) (phosphatidylinositol or PI), as well as several other phospholipids (1,2-diacyl-sn-glycero-3-phosphocholine, 1,2-diacyl-sn-glycero-3-phosphoethanolamine), and N-acetylglucosaminylphosphatidylinositol (GlcNAc-PI) in vitro (PubMed:35344438)

The "CLPTM1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLPTM1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets